줄기세포 치료 시장 : 치료 유형별, 세포원별, 최종사용자별, 용도별, 치료 분야별 - 세계 예측(2025-2030년)

The Stem Cell Therapy Market was valued at USD 3.91 billion in 2023 and is projected to grow to USD 4.45 billion in 2024, with a CAGR of 14.27%, reaching USD 9.95 billion by 2030.

Stem cell therapy represents one of the most promising frontiers in modern medicine, opening new avenues for regenerative treatments and disease management. This innovative field harnesses the distinctive properties of stem cells to repair damaged tissues, restore functionality, and offer patients hope where conventional treatments may fall short. In recent years, extensive research has driven a better understanding of the underlying biology of stem cells, paving the way for breakthrough therapies that target a range of conditions from degenerative disorders to acute injuries.

The continuous refinement in cell isolation techniques, culture methods, and genomic profiling has not only increased the safety and efficacy of these therapies but also expanded their potential applications. As the scientific community and regulatory bodies work more closely to establish frameworks and protocols, the integration of stem cell technology into mainstream healthcare is becoming increasingly feasible. This introduction sets the stage for a broader discussion on how emerging trends and technological advances are reshaping the landscape, ushering in a new era of personalized and regenerative medicine.

By embracing interdisciplinary research, fostering public and private partnerships, and maintaining robust clinical validations, the stem cell therapy market is poised to transform both clinical practices and patient outcomes in a manner that was once considered out of reach.

Transformative Shifts in the Stem Cell Therapy Landscape

Recent years have been marked by transformative shifts in the landscape of stem cell therapy, driven by rapid scientific advancements and evolving market dynamics. The integration of state-of-the-art biotechnologies has facilitated the progression from experimental phases to clinically approved treatments, thereby redefining therapeutic strategies across diverse medical disciplines. Innovative methods in cell reprogramming, enhanced culture conditions, and precision medicine have collectively contributed to a paradigm shift where personalized care is becoming a tangible reality.

This evolution is underpinned by a deeper scientific understanding of stem cell behavior that has enabled researchers to overcome previous limitations related to cell viability and differentiation. Research and clinical trials have not only highlighted the therapeutic potential of both allogeneic and autologous approaches but have also underscored the importance of harnessing varied cell sources such as adult, embryonic, induced pluripotent, and perinatal stem cells.

The emergence of rigorous regulatory paths, combined with technological advancements, continues to instill confidence in stakeholders. Economic considerations, funding opportunities, and strategic collaborations are further accelerating the pace of innovation in this sector. As market drivers converge, the result is an industry that is more resilient, data-driven, and capable of addressing complex healthcare challenges through regenerative medicine.

Comprehensive Market Segmentation Insights in Stem Cell Therapy

Understanding the nuances of market segmentation is critical to navigating the complex ecosystem of stem cell therapy. The market analysis is driven by multiple segmentation factors that quantify the diversity in treatment modalities and research applications. One primary segmentation is based on therapy type, where the market is evaluable both under allogeneic and autologous approaches. Each method brings distinct advantages, whether deriving stem cells from donors or patients themselves, thereby influencing safety, efficacy, and personalized treatment options.

A second pivotal dimension is the investigation based on cell source. The research examines adult stem cells, embryonic stem cells, induced pluripotent stem cells, and perinatal stem cells to discern their therapeutic potential and limitations. Adult stem cells receive further analytical attention, particularly through the study of hematopoietic, mesenchymal, and neural stem cells, each contributing unique properties that influence treatment outcomes. Similarly, perinatal stem cells are scrutinized by evaluating amniotic fluid, placental, and umbilical cord sources. This granular breakdown provides insights into the relative merits and clinical applicability of each cell type.

The market is further divided according to end user segments-academic and research institutions, biotechnology and pharmaceutical companies, and hospitals and specialty clinics. Such segmentation reflects the varying demands for research innovation, therapy development, and patient-centered treatment models. Additionally, the application-based segmentation emphasizes the utilization of stem cell therapies in drug discovery and development, regenerative medicine, and tissue engineering. Another segmentation area focuses on therapeutic areas, where cardiovascular diseases, hematology, musculoskeletal disorders, neurological disorders, and oncology are the primary targets of regenerative interventions. This multidimensional analysis not only highlights the expansive application of stem cell research but also underscores the tailored approaches that are required to address specific medical challenges.

Based on Therapy Type, market is studied across Allogeneic Therapy and Autologous Therapy.

Based on Cell Source, market is studied across Adult Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells, and Perinatal Stem Cells. The Adult Stem Cells is further studied across Hematopoietic Stem Cells, Mesenchymal Stem Cells, and Neural Stem Cells. The Perinatal Stem Cells is further studied across Amniotic Fluid Stem Cells, Placental Stem Cells, and Umbilical Cord Stem Cells.

Based on End User, market is studied across Academic & Research Institutions, Biotechnology & Pharmaceutical Companies, and Hospitals & Specialty Clinics.

Based on Application, market is studied across Drug Discovery and Development, Regenerative Medicine, and Tissue Engineering.

Based on Therapeutic Areas, market is studied across Cardiovascular Diseases, Hematology, Musculoskeletal Disorders, Neurological Disorders, and Oncology.

Global Regional Dynamics in the Stem Cell Therapy Market

Regional dynamics play a crucial role in mapping the global landscape of stem cell therapy. Market trends and regulatory approvals exhibit distinct patterns across different regions. In the Americas, robust investment in biomedical research and well-established healthcare infrastructures are significant drivers for the adoption of advanced stem cell therapies. The region's diverse population and proactive public-private partnerships have spurred rapid development and clinical trials that continue to influence global standards.

Meanwhile, in regions encompassing Europe, the Middle East, and Africa, a blend of tradition and innovation is pushing forward progressive healthcare agendas. Researchers and policymakers in these areas are increasingly focused on developing localized therapies that address region-specific health challenges while aligning with international protocols. The strengthening of regulatory frameworks in these regions further supports the safe and effective integration of stem cell therapies into routine clinical practice.

In the Asia-Pacific region, rapid economic growth combined with a significant increase in research funding has positioned the area as a burgeoning hub for biotechnology and regenerative medicine. Driven by expansive clinical research, technological adoption, and a rising middle-class demand for advanced healthcare solutions, the Asia-Pacific markets are progressively adopting novel stem cell therapies. This tripartite regional overview provides a comprehensive understanding of how local trends, regulatory environments, and economic factors interplay to shape the global market landscape of stem cell therapy.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Steering Stem Cell Therapy Advancements

Numerous pioneering companies are at the vanguard of driving advancements in the stem cell therapy space. Industry leaders such as Anterogen Co., Ltd. and Astellas Pharma Inc. are continuously adopting innovative approaches to developing breakthrough therapies. These companies, along with emerging innovators like Beike Biotechnology Co., Ltd. and BrainStorm Cell Therapeutics Inc., are instrumental in translating cutting-edge research into clinically effective solutions. Notable pharmaceutical giants like Bristol-Myers Squibb Company and Kite Pharma, Inc. under Gilead Sciences, Inc. have also contributed significantly by leveraging their extensive research networks and global resources to propel stem cell therapies forward.

Other prominent market players, including CellProthera SAS, Fate Therapeutics, Inc., and Gamida Cell Ltd., are recognized for their focus on enhancing the differentiation processes and ensuring consistent quality across therapeutic applications. Companies such as Garuda Therapeutics and Holostem Terapie Avanzate S.r.l. have further diversified the landscape by exploring novel cell sources and addressing unmet clinical needs. Jasper Therapeutics, Inc. and JCR Pharmaceuticals Co., Ltd. are continuously pushing the envelope for clinical innovation, while Juvena Therapeutics Inc., Kangstem Biotech Co., Ltd., and Lonza Group AG play critical roles by ensuring the scalability and reliability of stem cell production.

In addition, organizations like Medeze Group, Merck KGaA, and Mesoblast Ltd. are investing in research and development to establish next-generation treatment protocols. Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, and SQZ Biotechnologies Company by Stemcell Technologies are leveraging the latest in cellular engineering to expand therapeutic frontiers. Finally, companies such as Takara Bio Inc., Thermo Fisher Scientific Inc., U.S. Stem Cell Inc., Umoja Biopharma, and Vericel Corporation round out the comprehensive list of key players whose consistent innovation and market presence are setting the pace for the future of stem cell therapy. Each of these companies not only contributes technological expertise and clinical experience but also serves as a benchmark for excellence in advancing regenerative medicine.

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Astellas Pharma Inc., Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera SAS, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech Co., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lonza Group AG, Medeze Group, Merck KGaA, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, SQZ Biotechnologies Company by Stemcell Technologies, Takara Bio Inc., Thermo Fisher Scientific Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation. Strategic Recommendations for Maximizing Growth in Stem Cell Therapy

In an evolving industry characterized by rapid advancements and regulatory complexities, industry leaders must adopt strategic measures to sustain growth in the field of stem cell therapy. First, it is essential to continuously invest in research and development to not only improve the therapeutic efficiency of existing modalities but also to discover novel approaches that could address emerging clinical challenges. Maintaining strong collaborations with academic research institutions and global biotechnological networks will enable companies to stay at the forefront of innovation.

Second, companies should prioritize the implementation of rigorous quality control measures and standardized manufacturing processes. This approach will ensure safety, enhance scalability, and promote regulatory compliance throughout the entire production lifecycle. Embracing digital transformations-such as integrating data analytics and artificial intelligence into research pipelines-could provide sharper insights into clinical outcomes and operational efficiencies.

Third, industry stakeholders must tailor their strategies to the unique demands of different regional markets. Customized solutions that account for local regulatory frameworks and market maturity can significantly enhance market penetration and clinical acceptance. It is equally important to build strong, trust-based relationships with healthcare providers by offering continuous education, technical support, and transparent communication regarding the benefits and limitations of various therapies.

Finally, proactive engagement with regulatory bodies is crucial. Keeping abreast of policy changes and participating in shaping future guidelines can preempt regulatory challenges and facilitate smoother market entry. By combining innovation, operational excellence, and strategic regional focus, companies can effectively navigate the competitive landscape and drive sustained growth in the therapeutic domain.

Executive Summary Conclusion: The Future of Stem Cell Therapy

As the stem cell therapy market matures, the convergence of technological breakthroughs, evolving regulatory landscapes, and comprehensive segmentation strategies has painted a promising outlook for the future of regenerative medicine. The journey from laboratory innovation to clinical application is now marked by transformative shifts that are reshaping the standards of care in diverse therapeutic areas. From the rigorous analysis of therapy types and cell sources to the dynamic influence of regional markets and the relentless pursuit of technological excellence by key industry players, every facet of this ecosystem has contributed to building a robust, scalable, and patient-centric therapeutic paradigm.

The continuous evolution of therapeutic strategies coupled with strategic collaborations is further cementing the role of stem cell therapy as an essential component in modern medical practice. As clinical trials yield increasingly positive results and regulatory pathways become more clearly defined, the potential to address complex health issues with precision medicine grows stronger every day. Stakeholders are now presented with a unique opportunity to not only capitalize on these advancements but also to drive the next wave of clinical innovations that could redefine treatment protocols across boundaries.

In summary, the strategic foresight, collaborative efforts, and unwavering commitment to excellence in research and development are setting the stage for breakthroughs that will transform patient care globally. The industry is poised on the brink of a new era, one that promises to deliver enhanced therapeutic outcomes and improved quality of life for patients worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising aging global population and awareness about the therapeutic potential of stem cells
    • 5.1.1.2. Government initiatives and favorable regulatory frameworks are promoting stem cell research advancement
    • 5.1.1.3. Growing prevalence of chronic diseases is fueling the need for advanced stem cell therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with stem cell therapy limit accessibility for both patients and providers
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing public and private investment in research and development activities
    • 5.1.3.2. Advancements in cell-based technologies are enhancing the efficacy and applications of stem cell therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Navigating the varying regulatory landscape for stem cell therapies
    • 5.1.4.2. Ethical concerns and public perception surrounding the use of stem cells
• 5.2. Market Segmentation Analysis
  • 5.2.1. Therapy Type: Growing applications of autologous therapy owing to minimizing the risk of immune rejection and transmission of infectious diseases
  • 5.2.2. Cell Source: Proliferating significance of neural stem cells due to the ability to differentiate into various cell types within the central nervous system
  • 5.2.3. End User: Increasing adoption of stem cell therapy in biotechnology & pharmaceutical companies for addressing neurodegenerative diseases and cardiovascular disorders
  • 5.2.4. Application: Rising applications in drug discovery and development owing to their ability to model diseases
  • 5.2.5. Therapeutic Areas: Significant benefits of stem cell therapy in cardiovascular diseases owing to cardiac repair and regeneration
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Stem Cell Therapy Market, by Therapy Type

• 6.1. Introduction
• 6.2. Allogeneic Therapy
• 6.3. Autologous Therapy

7. Stem Cell Therapy Market, by Cell Source

• 7.1. Introduction
• 7.2. Adult Stem Cells
  • 7.2.1. Hematopoietic Stem Cells
  • 7.2.2. Mesenchymal Stem Cells
  • 7.2.3. Neural Stem Cells
• 7.3. Embryonic Stem Cells
• 7.4. Induced Pluripotent Stem Cells
• 7.5. Perinatal Stem Cells
  • 7.5.1. Amniotic Fluid Stem Cells
  • 7.5.2. Placental Stem Cells
  • 7.5.3. Umbilical Cord Stem Cells

8. Stem Cell Therapy Market, by End User

• 8.1. Introduction
• 8.2. Academic & Research Institutions
• 8.3. Biotechnology & Pharmaceutical Companies
• 8.4. Hospitals & Specialty Clinics

9. Stem Cell Therapy Market, by Application

• 9.1. Introduction
• 9.2. Drug Discovery and Development
• 9.3. Regenerative Medicine
• 9.4. Tissue Engineering

10. Stem Cell Therapy Market, by Therapeutic Areas

• 10.1. Introduction
• 10.2. Cardiovascular Diseases
• 10.3. Hematology
• 10.4. Musculoskeletal Disorders
• 10.5. Neurological Disorders
• 10.6. Oncology

11. Americas Stem Cell Therapy Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Stem Cell Therapy Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Stem Cell Therapy Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. REGiMMUNE and Kiji Therapeutics unite to advance Treg-focused stem cell therapies
  • 14.3.2. Evotec and Novo Nordisk partnership advances stem cell therapy innovations for scalable solutions
  • 14.3.3. Collaboration between Somite Therapeutics and OmniaBio Inc. aims to revolutionize stem cell therapy with AI-driven approaches for Duchenne muscular dystrophy
  • 14.3.4. Bioserve India's launch of advanced stem cell products propels innovative research and therapies in India's regenerative medicine landscape
  • 14.3.5. Cell BioEngines secures USD 2 million funding to advance 'off-the-shelf' hematopoietic stem cell therapies and initiate multicenter clinical trials
  • 14.3.6. OrganaBio revolutionizes advanced therapy development with on-demand GMP-compliant hematopoietic stem cells
  • 14.3.7. FDA expands approval for CARVYKTI as the first BCMA-targeted therapy advancing multiple myeloma treatment
  • 14.3.8. Strategic partnership accelerates stem cell therapy development through streamlined collaboration
  • 14.3.9. Fujifilm to Invest USD 200 Million in Cell Therapy Production
  • 14.3.10. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
  • 14.3.11. Merger between Selecta Biosciences and Cartesian Therapeutics pioneers RNA cell therapy advancements
  • 14.3.12. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
  • 14.3.13. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
  • 14.3.14. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
  • 14.3.15. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
  • 14.3.16. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
  • 14.3.17. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
  • 14.3.18. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
  • 14.3.19. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
  • 14.3.20. Novo Nordisk to Expand R&D Presence in Greater Boston Area
  • 14.3.21. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
  • 14.3.22. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
  • 14.3.23. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 14.4.2. JCR Pharmaceuticals Co., Ltd.
  • 14.4.3. Novo Nordisk A/S
  • 14.4.4. Astellas Pharma Inc.

Companies Mentioned

• 1. Anterogen Co., Ltd.
• 2. Astellas Pharma Inc.
• 3. Beike Biotechnology Co., Ltd.
• 4. BrainStorm Cell Therapeutics Inc.
• 5. Bristol-Myers Squibb Company
• 6. CellProthera SAS
• 7. Fate Therapeutics, Inc.
• 8. Gamida Cell Ltd.
• 9. Garuda Therapeutics
• 10. Holostem Terapie Avanzate S.r.l.
• 11. Jasper Therapeutics, Inc.
• 12. JCR Pharmaceuticals Co., Ltd.
• 13. Juvena Therapeutics Inc.
• 14. Kangstem Biotech Co., Ltd.
• 15. Kite Pharma, Inc. by Gilead Sciences, Inc.
• 16. Lonza Group AG
• 17. Medeze Group
• 18. Merck KGaA
• 19. Mesoblast Ltd.
• 20. Novo Nordisk A/S
• 21. Plasticell
• 22. ReNeuron Group PLC
• 23. SQZ Biotechnologies Company by Stemcell Technologies
• 24. Takara Bio Inc.
• 25. Thermo Fisher Scientific Inc.
• 26. U.S. Stem Cell Inc
• 27. Umoja Biopharma
• 28. Vericel Corporation